In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus

Abstract Objective In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral respiratory infections and also contain compounds that might directly inhibit 2019 novel coronavirus (2019-nCoV), an ongoing novel coronavirus that causes pneumonia. Methods There were two main steps in the screening process. In the first step we conducted a literature search for natural compounds that had been biologically confirmed as against sever acute respiratory syndrome coronavirus or Middle East respiratory syndrome coronavirus. Resulting compounds were cross-checked for listing in the Traditional Chinese Medicine Systems Pharmacology Database. Compounds meeting both requirements were subjected to absorption, distribution, metabolism and excretion (ADME) evaluation to verify that oral administration would be effective. Next, a docking analysis was used to test whether the compound had the potential for direct 2019-nCoV protein interaction. In the second step we searched Chinese herbal databases to identify plants containing the selected compounds. Plants containing 2 or more of the compounds identified in our screen were then checked against the catalogue for classic herbal usage. Finally, network pharmacology analysis was used to predict the general in vivo effects of each selected herb. Results Of the natural compounds screened, 13 that exist in traditional Chinese medicines were also found to have potential anti-2019-nCoV activity. Further, 125 Chinese herbs were found to contain 2 or more of these 13 compounds. Of these 125 herbs, 26 are classically catalogued as treating viral respiratory infections. Network pharmacology analysis predicted that the general in vivo roles of these 26 herbal plants were related to regulating viral infection, immune/inflammation reactions and hypoxia response. Conclusion Chinese herbal treatments classically used for treating viral respiratory infection might contain direct anti-2019-nCoV compounds.

[1]  Y. K. Choi,et al.  Safe, high-throughput screening of natural compounds of MERS-CoV entry inhibitors using a pseudovirus expressing MERS-CoV spike protein , 2018, International Journal of Antimicrobial Agents.

[2]  K. Park,et al.  Papain-like protease (PLpro) inhibitory effects of cinnamic amides from Tribulus terrestris fruits. , 2014, Biological & pharmaceutical bulletin.

[3]  G. Panayiotakopoulos,et al.  Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event , 2020, bioRxiv.

[4]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[5]  K.-C. Chou,et al.  Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy , 2006, Amino Acids.

[6]  H. Tian.  [2019-nCoV: new challenges from coronavirus]. , 2020, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine].

[7]  Syed Mohd. Danish Rizvi,et al.  A simple click by click protocol to perform docking: AutoDock 4.2 made easy for non-bioinformaticians , 2013, EXCLI journal.

[8]  Wenling Wang,et al.  High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses , 2019, Journal of Virology.

[9]  Mitchell A. Avery,et al.  Inhibitors of SARS-3CLpro: Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation Studies , 2011, J. Chem. Inf. Model..

[10]  H. Ploegh,et al.  Ubiquitination, Ubiquitin-like Modifiers, and Deubiquitination in Viral Infection , 2009, Cell Host & Microbe.

[11]  Yang Yang,et al.  A Network Pharmacology Study on the Active Ingredients and Potential Targets of Tripterygium wilfordii Hook for Treatment of Rheumatoid Arthritis , 2019, Evidence-based complementary and alternative medicine : eCAM.

[12]  Rolf Hilgenfeld,et al.  Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.

[13]  G. Gao,et al.  Crystal Structure of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fusion Core* , 2004, Journal of Biological Chemistry.

[14]  Y. Liu,et al.  Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase. , 2006, Current pharmaceutical design.

[15]  A. J. Kesel.  Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS). , 2005, Current medicinal chemistry.

[16]  P. Xiao,et al.  Identification of natural compounds with antiviral activities against SARS-associated coronavirus , 2005, Antiviral Research.

[17]  Young Min Kim,et al.  SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii , 2010, Bioorganic & Medicinal Chemistry Letters.

[18]  Airong Qian,et al.  Systems Pharmacology for Investigation of the Mechanisms of Action of Traditional Chinese Medicine in Drug Discovery , 2019, Front. Pharmacol..

[19]  Doman Kim,et al.  Dieckol, a SARS-CoV 3CLpro inhibitor, isolated from the edible brown algae Ecklonia cava , 2013, Bioorganic & Medicinal Chemistry.

[20]  H. Doerr,et al.  Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus. , 2005, Journal of medicinal chemistry.

[21]  Hsuan-Cheng Huang,et al.  Small molecules targeting severe acute respiratory syndrome human coronavirus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Zhijian J. Chen,et al.  Ubiquitylation in innate and adaptive immunity , 2009, Nature.

[23]  BING LIU,et al.  SARS‐CoV protease inhibitors design using virtual screening method from natural products libraries , 2005, J. Comput. Chem..

[24]  Po-Huang Liang,et al.  Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. , 2007, Journal of medicinal chemistry.

[25]  K. Park,et al.  Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors , 2017, Journal of enzyme inhibition and medicinal chemistry.

[26]  Tsuyoshi Nakamura,et al.  Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS , 2004, Phytotherapy research : PTR.

[27]  Cha Young Kim,et al.  Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV , 2016, Journal of enzyme inhibition and medicinal chemistry.

[28]  Raymond C Stevens,et al.  Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  K. Park,et al.  Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases , 2012, Bioorganic & Medicinal Chemistry.

[30]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[31]  Cheng Luo,et al.  Binding interaction of quercetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure–activity relationship studies reveal salient pharmacophore features , 2006, Bioorganic & Medicinal Chemistry.